公开(公告)号：US10428331B2

公开(公告)日：2019-10-01

申请号：US15107536

申请日：2015-01-14

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Ann-Marie Broome ,  Suraj Dixit ,  Satish Nadig ,  Carl Atkinson

IPC: A61K39/395 ,  C12N15/117 ,  A61K31/365 ,  A61K31/436 ,  A61K31/713 ,  A61K35/17 ,  A61K38/13 ,  A61K38/17 ,  A61K38/20 ,  C12N15/11 ,  A61K31/395 ,  A61K47/62 ,  A61K47/69 ,  A61K35/12

Abstract: Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.

公开(公告)号：US11344025B2

公开(公告)日：2022-05-31

申请号：US16339179

申请日：2018-12-26

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Satish N. Nadig ,  Carl Atkinson ,  Danh T. Tran

IPC: A01N1/02 ,  C07C251/86 ,  C07D239/95

Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation and for inducing mitochondrial morphological alterations.

公开(公告)号：US11214805B2

公开(公告)日：2022-01-04

申请号：US16548945

申请日：2019-08-23

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Ann-Marie Broome ,  Suraj Dixit ,  Satish Nadig ,  Carl Atkinson

IPC: A61K39/395 ,  C12N15/117 ,  A61K47/62 ,  A61K47/69 ,  A61K31/395 ,  A61K38/20 ,  C12N15/11 ,  A61K31/365 ,  A61K31/436 ,  A61K31/713 ,  A61K35/17 ,  A61K38/13 ,  A61K38/17 ,  A61K35/12

Abstract: Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.

公开(公告)号：US20200056183A1

公开(公告)日：2020-02-20

申请号：US16548945

申请日：2019-08-23

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Ann-Marie Broome ,  Suraj Dixit ,  Satish Nadig ,  Carl Atkinson

IPC: C12N15/117 ,  A61K38/17 ,  A61K38/13 ,  A61K35/17 ,  A61K31/713 ,  A61K31/436 ,  A61K31/365 ,  C12N15/11 ,  A61K38/20 ,  A61K31/395 ,  A61K47/69 ,  A61K47/62

Abstract: Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.

公开(公告)号：US20210388080A1

公开(公告)日：2021-12-16

申请号：US17228279

申请日：2021-04-12

Applicant: The Regents of The University of Colorado, A Body Corporate ,  MUSC Foundation For Research Development ,  United States Government as Represented by the Department of Veterans Affairs

Inventor： Baerbel M. Rohrer ,  V. Michael Holers ,  Stephen Tomlinson ,  Joshua M. Thurman ,  Carl Atkinson ,  Liudmila Kulik

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The invention also provides methods of inhibiting complement-driven inflammation in the eye in an individual, comprising administering to the individual an antibody or a fragment thereor or compositions thereof, wherein the antibody or fragment thereof specifically binds to Annexin IV or phospholipid. Also provided are related methods of treating a complement-associated ocular disease or an ocular disease involving oxidative damage. Additionally, the invention provides methods of detecting complement-mediated injury in an eye tissue of an individual, comprising administering to the individual a construct or compositions thereof, wherein the construct comprises (a) an antibody or fragment thereof that specifically binds to Annexin IV or phospholipid; and (b) a detectable moiety.

公开(公告)号：US11260027B2

公开(公告)日：2022-03-01

申请号：US15745913

申请日：2016-06-24

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Satish Nadig ,  Carl Atkinson ,  Ann-Marie Broome ,  Suraj K. Dixit

IPC: A61K9/107 ,  A61K9/127 ,  A61K38/13 ,  A61K9/51 ,  A01N1/02 ,  A61K31/436 ,  A61K31/365 ,  A61K38/20 ,  A61K31/713 ,  A61P37/06 ,  A61K31/343 ,  A61K47/10 ,  A61K31/453 ,  B82Y5/00

Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation, comprising a therapeutically effective amount of an immunosuppressive agent encapsulated in a micelle, liposome or polymeric nanoparticle that comprises on its surface a targeting moiety.

公开(公告)号：US20200281190A1

公开(公告)日：2020-09-10

申请号：US16339179

申请日：2018-12-26

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Satish N. Nadig ,  Carl Atkinson ,  Danh T. Tran

IPC: A01N1/02 ,  C07C251/86 ,  C07D239/95

Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation and for inducing mitochondrial morphological alterations.

公开(公告)号：US20160317670A1

公开(公告)日：2016-11-03

申请号：US15107536

申请日：2015-01-14

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Ann-Marie Broome ,  Suraj Dixit ,  Satish Nadig ,  Carl Atkinson

IPC: A61K47/48 ,  A61K38/13 ,  A61K31/713 ,  A61K31/365 ,  A61K35/17 ,  C12N15/117 ,  A61K31/436 ,  A61K38/17

CPC classification number: C12N15/117 ,  A61K31/365 ,  A61K31/395 ,  A61K31/436 ,  A61K31/713 ,  A61K35/17 ,  A61K38/13 ,  A61K38/1793 ,  A61K38/2013 ,  A61K47/62 ,  A61K47/6909 ,  A61K2035/124 ,  C12N15/111 ,  C12N2310/14 ,  C12N2310/17 ,  C12N2320/32

Abstract: Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.

Abstract translation: 公开了一种靶向C3分解产物，整联蛋白或其组合的纳米载体免疫抑制剂，以减少免疫抑制剂的有害全身效应。 还公开了抑制受试者中同种异体免疫应答的方法，例如可以在同种异体移植后发生的同种异体免疫应答。